In describing the chemical class of CYP8B1 inhibitors, it's important to note that many of these inhibitors are not specific to CYP8B1 but rather affect a range of cytochrome P450 enzymes. This class of inhibitors often includes compounds with antifungal and antiviral properties. These inhibitors commonly function by binding to the heme-iron component of the P450 enzymes, a crucial part of their catalytic activity. This binding interferes with the enzyme's ability to metabolize its substrates, thereby inhibiting its activity.
The diversity in the chemical structures of these inhibitors, ranging from azoles (like ketoconazole and fluconazole) to kinase inhibitors (like erlotinib and sorafenib), reflects the broad approach in targeting the P450 enzyme family. While some inhibitors, particularly the azoles, act through a more direct interaction with the heme-iron, others may inhibit CYP8B1 as part of a broader inhibition of multiple enzymes and pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
A broad-spectrum antifungal agent that inhibits CYP8B1 by binding to the heme group in the P450 enzyme. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
An imidazole antifungal known to inhibit P450 enzymes, including CYP8B1, through heme-iron binding. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $66.00 $160.00 | 2 | |
Part of the imidazole class, known for inhibiting P450 enzymes, potentially interacting with CYP8B1's heme-iron. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
A triazole antifungal that inhibits P450 enzymes, possibly affecting CYP8B1 through heme group interaction. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
A triazole antifungal with potential inhibitory effect on CYP8B1 among its broader P450 inhibitory actions. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
A kinase inhibitor shown to affect various P450 enzymes, potentially including CYP8B1. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
A kinase inhibitor that might also inhibit CYP8B1 as part of its impact on cytochrome P450 enzymes. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A kinase inhibitor with broad effects, potentially affecting CYP8B1 activity. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
An HIV protease inhibitor known to inhibit various cytochrome P450 enzymes, potentially including CYP8B1. | ||||||
Nelfinavir | 159989-64-7 | sc-507314 | 10 mg | $168.00 | ||
An HIV protease inhibitor with a profile of inhibiting multiple P450 enzymes, likely impacting CYP8B1. | ||||||